BRISTOL MYERS SQUIBB

🇫🇷France
Ownership
-
Established
1989-01-01
Employees
30K
Market Cap
$97.5B
Website
https://www.bms.com/
Clinical Trials
Related News

A Study to Assess the Relative Bioavailability of 5 mg Mavacamten Opened Capsule Administered Via Nasogastric Tube Compared to Intact Oral 5 mg Mavacamten in Healthy Participants

Phase 1
Recruiting
Conditions
Healthy Volunteers
First Posted Date
2024-01-18
Last Posted Date
2024-03-01
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
36
Registration Number
NCT06211179
Locations
🇺🇸

Local Institution - 0001, San Antonio, Texas, United States

A Lactation Study in Women Receiving Treatment With Ozanimod

First Posted Date
2023-12-26
Last Posted Date
2023-12-26
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
16
Registration Number
NCT06181630

A Study to Assess Health-Related Quality of Life in Patients With Hypertrophic Cardiomyopathy in Japan

First Posted Date
2023-12-26
Last Posted Date
2024-05-03
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
470
Registration Number
NCT06181617
Locations
🇯🇵

Mebix. Inc, Minato-ku, Tokyo, Japan

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany

First Posted Date
2023-12-14
Last Posted Date
2024-04-18
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
400
Registration Number
NCT06169956
Locations
🇩🇪

Klinikverbund Allgaeu, Kempten, Bayern, Germany

A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home

Recruiting
Conditions
Cancer
Solid Tumors
Interventions
Drug: Immunotherapy
First Posted Date
2023-12-08
Last Posted Date
2023-12-08
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
150
Registration Number
NCT06163053
Locations
🇫🇷

CH Francois Quesnay, Mantes-La-Jolie, France

🇫🇷

CH de Pau, Pau, France

🇫🇷

CH Metropole Savoie, Chambéry, France

A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

First Posted Date
2023-12-08
Last Posted Date
2024-09-30
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
27
Registration Number
NCT06163040
Locations
🇨🇳

China Medical University Hospital, Taoyuan City, Taiwan

🇨🇳

Chang Gung Memorial Hospital- Chiayi, Chiayi City, Chiayi, Taiwan

🇨🇳

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan

and more 1 locations

A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma

First Posted Date
2023-12-08
Last Posted Date
2024-04-18
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
100
Registration Number
NCT06163170
Locations
🇺🇸

Cardinal Health, Dublin, Ohio, United States

Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs

First Posted Date
2023-12-07
Last Posted Date
2024-08-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
4204
Registration Number
NCT06160167
Locations
🇺🇸

Flatiron Health Oncology Database, New York, New York, United States

Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel

Active, not recruiting
Conditions
Multiple Myeloma
Interventions
Other: Not treated
Drug: Idecabtagene vicleucel
First Posted Date
2023-12-04
Last Posted Date
2023-12-04
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
350
Registration Number
NCT06154902
Locations
🇫🇷

DESCAR-T Registry, Paris, France

A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

First Posted Date
2023-11-27
Last Posted Date
2024-11-06
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
600
Registration Number
NCT06146660
Locations
🇰🇷

Local Institution - 0001, Seoul, Korea, Republic of

🇰🇷

Novotech Laboratory Korea Co., Ltd., Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy